
Mirati Stock Sale Targets $ 200M as Lead Cancer Drug Starts Phase 3 Xconomy
Mirati Therapeutics plans to raise more than $ 200 million this week in a public offering, funding that it plans to use to advance its lead cancer drug.

Mirati Stock Sale Targets $ 200M as Lead Cancer Drug Starts Phase 3 Xconomy
Mirati Therapeutics plans to raise more than $ 200 million this week in a public offering, funding that it plans to use to advance its lead cancer drug.